W. C. Lumma

发表

Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.

W. M. Sanders, T. Tucker, M. Goldman, 1994, Journal of Medicinal Chemistry.

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

P. Anderson, W. Schleif, E. Emini, 1995, Antimicrobial agents and chemotherapy.

Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 position.

J. Vacca, S. Gardell, T. Tucker, 1997, Journal of medicinal chemistry.

2-Arylindole-3-acetamides: FPP-competitive inhibitors of farnesyl protein transferase.

N. Kohl, R. Lobell, C. Buser, 2001, Bioorganic & medicinal chemistry letters.

The role of intramolecular hydrogen bonding as a determinant of the conformational profiles of cGMP and cAMP

M. Sabio, W. C. Lumma, S. Topiol, 1990 .

Preclinical Models Geranylgeranyl : Protein Transferase Inhibitor Combinations in Evaluation of Farnesyl : Protein Transferase and Updated

A. Kral, D. Heimbrook, J. Davide, 2001 .

Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.

R. DeVita, D. Davey, R. Gomez, 1987, Journal of medicinal chemistry.

An investigation of tautomerism in adenine and guanine

M. Sabio, W. C. Lumma, S. Topiol, 1990 .

SYMBIOTIC APPROACH TO DRUG DESIGN: ANTIHYPERTENSIVE β-ADRENERGIC BLOCKING AGENTS

G. F. Lundell, G. Ponticello, J. Baldwin, 1980 .

Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.

J. Vacca, S. Gardell, T. Tucker, 1997, Journal of medicinal chemistry.

Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.

S. Brady, J. Vacca, S. Gardell, 1998, Journal of medicinal chemistry.

Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesis.

S. Brady, J. Vacca, T. Tucker, 1998, Journal of medicinal chemistry.

Synthesis of novel 3-(alkylthio)-2-halopyridines and related derivatives

G. Ponticello, J. Baldwin, W. C. Lumma, 1979 .

Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site.

R. Freidinger, L. Kuo, Z. Chen, 1997, Journal of medicinal chemistry.

Modification of the Passerini reaction: facile synthesis of analogs of isoproterenol and (aryloxy)propanolamine .beta.-adrenergic blocking agents

W. C. Lumma, 1981 .

Piperazinylquinoxalines with central serotoninmimetic activity.

C. A. Stone, V. J. Lotti, E. Engelhardt, 1981, Journal of Medicinal Chemistry.

Novel condensation of 2,3-epoxybutanal with 2-aminopyridine and 2-aminopyrazine. Synthesis and stability of 3-(1-hydroxyethyl)imidazo[1,2-a]azines

J. Springer, W. C. Lumma, 1981 .

A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity.

P. Darke, W. Schleif, T. Tucker, 1992, Journal of medicinal chemistry.

The chemistry of cephamycins. IV. Acylation of amides in the presence of neutral acid scavengers

W. C. Lumma, S. Karady, M. Sletzinger, 1975 .

PIPERAZINYLQUINOXALINES WITH CENTRAL SEROTONINMIMETIC ACTIVITY

C. A. Stone, V. J. Lotti, E. Engelhardt, 1981 .

Cardiotonic agents. 1. Novel 8-aryl-substituted imidazo[1,2-a]- and -[1,5-a]pyridines and imidazo[1,5-a]pyridinones as potential positive inotropic agents.

P. Erhardt, D. Davey, W. C. Lumma, 1987, Journal of medicinal chemistry.

Convenient synthesis of 4-methylhistamine and racemic .alpha.,4-dimethylhistamine and .alpha.,4-dimethylhistidine

D. Davey, W. C. Lumma, 1989 .

Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.

G. Phillips, R. Gomez, W. C. Lumma, 1992, Journal of medicinal chemistry.

Piperazinylpyrazines with central serotoninmimetic activity.

C. A. Stone, E. Engelhardt, R. Hirschmann, 1978, Journal of medicinal chemistry.

Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.

G. F. Lundell, G. Ponticello, J. Baldwin, 1979, Journal of medicinal chemistry.

Inhibitoren der phenyl-protein-transferase

W. C. Lumma, J. Sisko, A. Smith, 2000 .

Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.

A. Kral, D. Heimbrook, J. Davide, 2001, Cancer research.

β-Methylsulfonylamino phenethylamines and aryloxypropylamines as potential β-adrenergic agents

M. Sabio, P. Erhardt, W. C. Lumma, 1987 .

Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds.

S. Wong, R. DeVita, D. Davey, 1987, Journal of medicinal chemistry.

Anions Modulate the Potency of Geranylgeranyl-Protein Transferase I Inhibitors*

D. Heimbrook, R. Lobell, C. Buser, 2001, The Journal of Biological Chemistry.

2-Heterocyclic indole-3-sulfones as inhibitors of HIV-1 reverse transcriptase

W. Schleif, J. Huff, J. O'brien, 1995 .

Inhibitors of gastric acid secretion: 3,4-diamino-1,2,5-thiadiazole 1-oxides and 1,1-dioxides as urea equivalents in a series of histamine H2-receptor antagonists.

B. T. Phillips, P. Anderson, J. Hirshfield, 1982, Journal of medicinal chemistry.

Statins suppress THP‐1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation

S. Wright, W. C. Lumma, J. Sisko, 2001, Journal of leukocyte biology.

Structure-activity studies and antiviral properties of hydroxyethylene transition state inhibitors of HIV-1 protease

P. Anderson, P. Darke, W. Schleif, 1992 .

Development of nonnucleoside HIV reverse transcriptase inhibitors.

T. Tucker, W. C. Lumma, J. Culberson, 1996, Methods in Enzymology.

Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds. 2.

D. Davey, C. Wan, W. C. Lumma, 1987, Journal of medicinal chemistry.

Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support.

S. Brady, J. Vacca, S. Gardell, 1998, Journal of medicinal chemistry.

Piperazinylimidazo[1,2-a]pyrazines with selective affinity for in vitro alpha-adrenergic receptor subtypes.

J. Huff, W. Randall, W. C. Lumma, 1983, Journal of medicinal chemistry.

The synthesis and biological evaluation of a series of potent dual inhibitors of farnesyl and geranyl-Geranyl protein transferases.

J. Davide, R. Lobell, J. Gibbs, 2002, Bioorganic & medicinal chemistry letters.

Synthesis of a Series of 4-(Arylethynyl)-6-chloro-4-cyclopropyl-3,4- dihydroquinazolin-2(1H)-ones as Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

W. M. Sanders, P. Anderson, W. Schleif, 1994 .